Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB treatment news

Show

From To
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Published
27 October 2014
From
TB Alliance
Bedaquiline as part of tailored therapy for MDR- and XDR-TB achieves impressive culture conversion rates

Use of the new anti-tuberculosis (TB) drug bedaquiline as part of a tailored regimen achieved high rates of culture conversion in people with multidrug-resistant TB (MDR-TB) and extensively

Published
27 October 2014
By
Michael Carter
Newly identified marker helps predict tuberculosis complications in HIV patients

An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop immune reconstitution inflammatory syndrome (IRIS).

Published
16 October 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
In HIV/TB coinfection, initiate antiretroviral therapy early

Earlier initiation of antiretroviral therapy (ART) significantly lowered mortality in patients with HIV and tuberculosis (TB) co-infection, despite a higher incidence of immune reconstitution inflammatory syndrome (IRIS), according to data presented at 2014 IDWeek.

Published
16 October 2014
From
Monthly Prescribing Reference (MPR)
What does new drug PaMZ mean for TB and HIV treatment?

The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

Published
02 September 2014
From
The Guardian
Acquired rifampicin resistance more likely in HIV-coinfected patients

Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India. The rate of bacteriologic failure was 4% among patients without HIV. Among patients with HIV, the rates were 9% for those not receiving ART and 5% for those receiving ART.

Published
02 September 2014
From
Healio
Use of drug susceptibility testing to select therapy improves treatment outcomes in patients with MDR- and XDR-TB

New research published in the online edition of Clinical Infectious Diseases supports World Health Organization (WHO) recommendations for the use of drug susceptibility testing to select drugs for the

Published
13 August 2014
By
Michael Carter
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test

Decentralisation of drug-resistant tuberculosis (DR-TB) management and use of the Xpert MTB/RIF test improves the time from clinic presentation to treatment from 50 days to 7 days

Published
23 July 2014
By
Lesley Odendal
From Rhetoric to Reality: An Analysis of Efforts to Scale Up The Response to TB-HIV

A new research report from ACTION global health shows that joint TB-HIV activities are neglected by HIV programs and overwhelmingly carried out by TB programs, and that global guidelines to address TB-HIV have not been prioritized by leading donors and affected countries.

Published
22 July 2014
From
ACTION
Novel TB regimen could reduce treatment duration

A novel TB drug regimen that could treat drug-sensitive and some forms of drug-resistant TB far more quickly than current standard TB therapy, according to findings from a

Published
21 July 2014
By
Lesley Odendal
← First12345...13Next →

Filter by country